The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.
Stefan Gluck
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Joyce O'Shaughnessy
Consultant or Advisory Role - Eisai
Kristi McIntyre
No relevant relationships to disclose
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Sharon Wilks
Consultant or Advisory Role - Eisai
Shannon Puhalla
Consultant or Advisory Role - Celldex; MedImmune; Pfizer
Erhan Berrak
Employment or Leadership Position - Eisai
James Song
Employment or Leadership Position - Eisai
David Cox
Employment or Leadership Position - Eisai
Linda T. Vahdat
Consultant or Advisory Role - Eisai